CURRENT PROSPECTS FOR THE TREATMENT OF DIABETES COMPLICATIONS
https://doi.org/10.21518/2079-701X-2016-9-12-17
Abstract
Arterial hypertension (AH) complicates the course of diabetes mellitus (DM) of both the 1st and 2nd type. In patients with diabetes type 1, the main cause of AH is diabetic nephropathy. In diabetes type 2, on the other hand, essential hypertension is diagnosed in 70-80% of cases. The choice of antihypertensive therapy in patients with diabetes is not easy; when selecting the best anti-hypertensive drug for a diabetes patient, the associated vascular complications should always be considered. Angiotensin-convertingenzyme inhibitors are the most common treatment of hypertension in diabetic patients. Damage of the nervous system - diabetic polyneuropathy (DPN) – is a key element in the clinical picture of diabetes. In the treatment of DPN, activation of neural regeneration (reinnervation) and pain management are crucial. Neurotropic B vitamins with multimodal effect play a key role in this.
About the Authors
M. Y. OGARKOV
Novokuznetsk State Institute of Advanced Medical Studies, Federal Agency for Healthcare and Social Development
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
Y. V. KOVALEVA
Novokuznetsk State Institute of Advanced Medical Studies, Federal Agency for Healthcare and Social Development
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
References
1. Савельева Л.В. Особенности тактики лечения больных ожирением и артериальной гипертонией. Ожирение. Метаболический синдром. Сахарный диабет 2 типа. Под ред. И.И. Дедова. М., 2000. С. 19-23. / Savelieva L.V. The specific treatment approach for patients with obesity and hypertension. Obesity. Metabolic syndrome. Diabetes mellitus type 2. Ed. by I.I. Dedov. М., 2000. P. 19-23.
2. WHO-ISH Guidelines Sub-Committee.1999 World Health Organisation – International Society of Hypertension Guidelines for the Manage ment of Hypertension. J Hypertens, 1999, 17: 151-83.
3. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of HOPE study and MICROHOPE substudy. Lancet, 2000, 355: 253-9.
4. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomised Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care, 1998, 21: 597-603.
5. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type 2 diabetes: UKPDS 38. Br Med J, 1998, 317: 703–713.
6. Беленков Ю.Н., Мареев Ю.В. Сердечно-сосудистый континуум. Сердечная недостаточность, 2002, 1: 7-11. / Belenkov Y.N., Mareyev V.Y. Cardiovascular continuum. Serdechnaya Nedostatochnost, 2002, 1: 7-11.
7. Vetter W. Treatment of senile hypertension: the Fosinopril in Old Patients Study (FOPS). Am J Hypertens, 1997, 10(10 Pt 2): 255S-261S.
8. Карпов Ю.А. Фозиноприл при лечении артериальной гипертонии (ФЛАГ): российская программа оценки практической достижимости целевых уровней артериального давления. РМЖ, 2001, 10: 3-7. / Karpov Y.A. Fosinopril in the treatment of hypertension (FLAG): Russian program for the evaluation of practicable achievability of target blood pressure levels. RMZ, 2001, 10: 3-7.
9. Holdaway IM, Gamble GD, Sanders GA et al. Effect of fosinopril on cardiac and metabolic
10. parameters in patients with NIDDM. Diabetes Care, 1994, 17(12): 1476-9.
11. Chang NC, Shih CM, Bi WF et al. Fosinopril improves left ventricular diastolic function in young mildly hypertensive patients without hypertrophy. Cardiovasc Drugs Ther, 2002, 16(2): 141-7.
12. Alli C, Lombardo M, Zanni D et al. Albuminuria and transferrinuria in essential hypertension. Effects of antihypertensive therapy. Am J Hypertens, 1996, 9(11): 1068-76.
13. Fogari R, Preti P, Zoppi A. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens, 2002, 15(12): 1042-9.
14. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care, 1998, 21(4): 597-603.
15. Carella MJ, Gossain VV, Jones J. The effects of a low-dose regimen of fosinopril on elevated urinary albumin excretion in normotensive type 1 diabetic patients. J Med, 1999, 30(5–6): 305-20.
16. Marin R, Ruilope LM, Aljama P, et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens, 2001;19(10):1871–6.
17. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation, 2004;110(18):2809–16.
18. Chang NC, Shih CM, Bi WF et al. Fosinopril improves left ventricular diastolic function in young mildly hypertensive patients without hypertrophy. Cardiovasc Drugs Ther, 2002, 16(2): 141-7.
19. Shigihara T, Sato A, Hayashi K, Saruta T. Effect of combination therapy of angiotensin- converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes. Hypert Res, 2000, 23: 219-26.
20. Ramsay LE, Williams B, Johnston GD, et al. Guidelines for management of hypertension: report of the working party of the British Hypertension Society. J Hum Hypert, 1999, 13: 69-92.
21. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk actors for type 2 diabetes. N Engl J Med, 2000, 342: 905-12.
22. Thornalley PJ, Babaei-Jadidi R, Al AH et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia, 2007; 50: 2164–70.
23. Hellmann H, Mooney S Review Vitamin B6: a molecule for human health? Molecules, 2010; 15 (1): 442–59.
24. O’Leary F, Samman S. Review Vitamin B12 in health and disease. Nutrients, 2010, 2(3): 299-316.
25. Molina M, Gonzalez R, Folgado J et al. Correlation between plasma concentrations of homocysteine and diabetic polyneuropathy evaluated with the Semmes-Weinstein sonofilament test in patients with type 2 diabetes mellitus. Med Clin (Barc.), 2013, 141(9): 382-6.
26. Токмакова А.Ю., Анциферов М.Б. Возможности использования Нейромультивита в комплексной терапии полинейропатии у больных сахарным диабетом. Сахарный диабет, 2001, 2(7): 33–35. / Tokmakova A.Y., Antsiferov M.B. Prospects for the use of Neuromultivit in the treatment of neuropathy in diabetic patients. Sakharniy Diabet, 2001, 2(7): 33-35.
Review
For citations:
OGARKOV MY, KOVALEVA YV. CURRENT PROSPECTS FOR THE TREATMENT OF DIABETES COMPLICATIONS. Meditsinskiy sovet = Medical Council. 2016;(9):12-17. (In Russ.) https://doi.org/10.21518/2079-701X-2016-9-12-17
Views:
697
Email this article 